Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5073757
Max Phase: Preclinical
Molecular Formula: C47H61N7O6S
Molecular Weight: 852.11
Molecule Type: Unknown
Associated Items:
ID: ALA5073757
Max Phase: Preclinical
Molecular Formula: C47H61N7O6S
Molecular Weight: 852.11
Molecule Type: Unknown
Associated Items:
Canonical SMILES: Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)CCCCCCCCCCC(=O)Nc2ccc(C(=O)Nc3ccccc3N)cc2)C(C)(C)C)cc1
Standard InChI: InChI=1S/C47H61N7O6S/c1-31-42(61-30-50-31)33-21-19-32(20-22-33)28-49-45(59)39-27-36(55)29-54(39)46(60)43(47(2,3)4)53-41(57)18-12-10-8-6-5-7-9-11-17-40(56)51-35-25-23-34(24-26-35)44(58)52-38-16-14-13-15-37(38)48/h13-16,19-26,30,36,39,43,55H,5-12,17-18,27-29,48H2,1-4H3,(H,49,59)(H,51,56)(H,52,58)(H,53,57)/t36-,39+,43-/m1/s1
Standard InChI Key: AQIQXAQNDASVRZ-IPQHXDNUSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 852.11 | Molecular Weight (Monoisotopic): 851.4404 | AlogP: 7.60 | #Rotatable Bonds: 20 |
Polar Surface Area: 195.85 | Molecular Species: NEUTRAL | HBA: 9 | HBD: 6 |
#RO5 Violations: 3 | HBA (Lipinski): 13 | HBD (Lipinski): 7 | #RO5 Violations (Lipinski): 4 |
CX Acidic pKa: 12.67 | CX Basic pKa: 3.24 | CX LogP: 5.75 | CX LogD: 5.75 |
Aromatic Rings: 4 | Heavy Atoms: 61 | QED Weighted: 0.04 | Np Likeness Score: -0.68 |
1. Smalley JP, Baker IM, Pytel WA, Lin LY, Bowman KJ, Schwabe JWR, Cowley SM, Hodgkinson JT.. (2022) Optimization of Class I Histone Deacetylase PROTACs Reveals that HDAC1/2 Degradation is Critical to Induce Apoptosis and Cell Arrest in Cancer Cells., 65 (7.0): [PMID:35293758] [10.1021/acs.jmedchem.1c02179] |
2. Cross JM, Coulson ME, Smalley JP, Pytel WA, Ismail O, Trory JS, Cowley SM, Hodgkinson JT.. (2022) A 'click' chemistry approach to novel entinostat (MS-275) based class I histone deacetylase proteolysis targeting chimeras., 13 (12.0): [PMID:36545434] [10.1039/d2md00199c] |
3. He X, Hui Z, Xu L, Bai R, Gao Y, Wang Z, Xie T, Ye XY.. (2022) Medicinal chemistry updates of novel HDACs inhibitors (2020 to present)., 227 [PMID:34775332] [10.1016/j.ejmech.2021.113946] |
Source(1):